Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.
Devos T, Geukens T, Schauwvlieghe A, Ariën KK, Barbezange C, Cleeren M, Compernolle V, Dauby N, Desmecht D, Grimaldi D, Lambrecht BN, Luyten A, Maes P, Moutschen M, Romano M, Seyler L, Nevessignsky MT, Vandenberghe K, van Griensven J, Verbeke G, Vlieghe E, Yombi JC, Liesenborghs L, Verhamme P, Meyfroidt G. Devos T, et al. Among authors: schauwvlieghe a. Trials. 2020 Dec 14;21(1):1024. doi: 10.1186/s13063-020-04947-2. Trials. 2020. PMID: 33317581 Free PMC article. No abstract available.
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.
Devos T, Geukens T, Schauwvlieghe A, Ariën KK, Barbezange C, Cleeren M, Compernolle V, Dauby N, Desmecht D, Grimaldi D, Lambrecht BN, Luyten A, Maes P, Moutschen M, Romano M, Seyler L, Nevessignsky MT, Vandenberghe K, van Griensven J, Verbeke G, Vlieghe E, Yombi JC, Liesenborghs L, Verhamme P, Meyfroidt G. Devos T, et al. Among authors: schauwvlieghe a. Trials. 2020 Nov 27;21(1):981. doi: 10.1186/s13063-020-04876-0. Trials. 2020. PMID: 33246499 Free PMC article. Clinical Trial.
Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma.
Devos T, Van Thillo Q, Compernolle V, Najdovski T, Romano M, Dauby N, Jadot L, Leys M, Maillart E, Loof S, Seyler L, Moonen M, Moutschen M, Van Regenmortel N, Ariën KK, Barbezange C, Betrains A, Garigliany M, Engelen MM, Gyselinck I, Maes P, Schauwvlieghe A, Liesenborghs L, Belmans A, Verhamme P, Meyfroidt G; DAWn-plasma investigators. Devos T, et al. Among authors: schauwvlieghe a. Eur Respir J. 2022 Feb 10;59(2):2101724. doi: 10.1183/13993003.01724-2021. Print 2022 Feb. Eur Respir J. 2022. PMID: 34446469 Free PMC article. Clinical Trial.
Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study.
Schauwvlieghe AFAD, Rijnders BJA, Philips N, Verwijs R, Vanderbeke L, Van Tienen C, Lagrou K, Verweij PE, Van de Veerdonk FL, Gommers D, Spronk P, Bergmans DCJJ, Hoedemaekers A, Andrinopoulou ER, van den Berg CHSB, Juffermans NP, Hodiamont CJ, Vonk AG, Depuydt P, Boelens J, Wauters J; Dutch-Belgian Mycosis study group. Schauwvlieghe AFAD, et al. Lancet Respir Med. 2018 Oct;6(10):782-792. doi: 10.1016/S2213-2600(18)30274-1. Epub 2018 Jul 31. Lancet Respir Med. 2018. PMID: 30076119
Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial.
Vanderbeke L, Janssen NAF, Bergmans DCJJ, Bourgeois M, Buil JB, Debaveye Y, Depuydt P, Feys S, Hermans G, Hoiting O, van der Hoven B, Jacobs C, Lagrou K, Lemiale V, Lormans P, Maertens J, Meersseman P, Mégarbane B, Nseir S, van Oers JAH, Reynders M, Rijnders BJA, Schouten JA, Spriet I, Thevissen K, Thille AW, Van Daele R, van de Veerdonk FL, Verweij PE, Wilmer A, Brüggemann RJM, Wauters J; Dutch-Belgian Mycosis Study Group. Vanderbeke L, et al. Intensive Care Med. 2021 Jun;47(6):674-686. doi: 10.1007/s00134-021-06431-0. Epub 2021 May 29. Intensive Care Med. 2021. PMID: 34050768 Free PMC article. Clinical Trial.
Point of care aspergillus testing in intensive care patients.
Mercier T, Dunbar A, Veldhuizen V, Holtappels M, Schauwvlieghe A, Maertens J, Rijnders B, Wauters J. Mercier T, et al. Among authors: schauwvlieghe a. Crit Care. 2020 Nov 10;24(1):642. doi: 10.1186/s13054-020-03367-7. Crit Care. 2020. PMID: 33168049 Free PMC article.
Stopping antibiotic therapy after 72 h in patients with febrile neutropenia following intensive chemotherapy for AML/MDS (safe study): A retrospective comparative cohort study.
Schauwvlieghe A, Dunbar A, Storme E, Vlak A, Aerts R, Maertens J, Sciot B, Van Der Wel T, Papageorgiou G, Moors I, Cornelissen JJ, Rijnders BJA, Mercier T. Schauwvlieghe A, et al. EClinicalMedicine. 2021 Apr 25;35:100855. doi: 10.1016/j.eclinm.2021.100855. eCollection 2021 May. EClinicalMedicine. 2021. PMID: 33997746 Free PMC article.
A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation.
Van Daele R, Bekkers B, Lindfors M, Broman LM, Schauwvlieghe A, Rijnders B, Hunfeld NGM, Juffermans NP, Taccone FS, Coimbra Sousa CA, Jacquet LM, Laterre PF, Nulens E, Grootaert V, Lyster H, Reed A, Patel B, Meersseman P, Debaveye Y, Wauters J, Vandenbriele C, Spriet I. Van Daele R, et al. Among authors: schauwvlieghe a. Microorganisms. 2021 Jul 20;9(7):1543. doi: 10.3390/microorganisms9071543. Microorganisms. 2021. PMID: 34361978 Free PMC article.
42 results